Showing results (101-110 of 227) with videos related to
Sort By:
Pageof 23
Leukemia & Lymphoma|October 6, 2007
The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantationGrant E Keeney, Ted A Gooley, Rosalyn N Pham, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2014
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphomaAjay K Gopal, Ted A Gooley, Joseph G Rajendran, et al.Leukemia & Lymphoma|June 11, 2014
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphomaTim Illidge, Reda Bouabdallah, Robert Chen, et al.British Journal of Haematology|May 27, 2009
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaAndres Forero-Torres, John P Leonard, Anas Younes, et al.Blood|February 17, 2007
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomasAnastasia Pantelias, John M Pagel, Nathan Hedin, et al.Journal of Clinical Pharmacology|June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignanciesTae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.American Journal of Hematology|July 1, 2016
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapyDaphne Y Xiao, Suhong Luo, Katiuscia O'Brian, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 21, 2018
Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell LymphomaCamille E Puronen, Ryan D Cassaday, Philip A Stevenson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2018
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced CancerNeil H Segal, Aiwu R He, Toshihiko Doi, et al.Cancer Medicine|November 18, 2021
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trialSriram Balasubramanian, Brendan Hodkinson, Stephen J Schuster, et al.Pageof 23